Research Article

Clinical Differences between Early- and Late-Onset Asthma: A Population-Based Cross-Sectional Study

Jiaming Li, Ling Ye, Jun She, and Yuanlin Song

Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China

Correspondence should be addressed to Jun She; shejun@163.com and Yuanlin Song; song.yuanlin@zs-hospital.sh.cn

Received 25 August 2020; Accepted 15 December 2020; Published 12 January 2021

Academic Editor: Andrea S. Melani

Copyright © 2021 Jiaming Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Limited information exists about the nature of late-onset asthma (LOA) without medication intervention when compared to early-onset asthma (EOA). Our goal was to understand how EOA and LOA affect clinical and pathophysiological features.

Methods. A population-based cross-sectional study was carried out in Zhongshan Hospital (Shanghai, China). EOA and LOA were based on age of diagnosis (before and after age 40 years, respectively). Clinical variables were collected with an emphasis on allergic features, analyzed, related, and compared using one-way ANOVA or Kruskal-Wallis test. Correlations between blood basophils and clinical data were evaluated by Spearman’s rank test. Statistical analyses were conducted with SPSS v24.0. Results. Of a total of 12,760 adults with cough, sputum, or chest tightness, 90 subjects with EOA (mean age ± standard deviation (SD): 28.73 ± 5.89), 111 with LOA (mean age ± SD: 60.25 ± 9.85), and 106 with chronic obstructive pulmonary disease (COPD) (mean age ± SD: 61.58 ± 10.95) were selected. FEV₁/FVC (%), FEV₁% predicted, and FVC% predicted were all significantly lower in LOA compared to EOA (p < 0.01). The values of post-bronchodilator FEV₁ in bronchodilator reversibility testing were higher in the LOA and EOA groups compared to subjects with COPD (p < 0.01). Among allergic features, mite sensitization was most common in EOA patients, followed by LOA and COPD, whereas mold sensitization was more prevalent in LOA than EOA. Moreover, blood eosinophils were a typical feature of asthma in both EOA and LOA compared to COPD and controls (p < 0.01), and there were no differences in blood neutrophils in LOA compared to controls. Interestingly, blood basophils were increased in both EOA (p < 0.01) and LOA (p < 0.05) compared to COPD and controls. This variable correlated with eosinophils in EOA (r = 0.549, p = 0.002) but not in LOA. Conclusion. LOA is a distinct clinical entity from EOA. In EOA, blood basophils and eosinophils were significantly correlated owing to pathophysiological differences between the two forms of the disease.

1. Introduction

Asthma is one of the major global health problems and contributes substantially to the worldwide burden of disease [1, 2]. Prevalence of adult asthma ranges from 2.8% to 15.7% in young adults and up to 10% in older adults aged over 65 years. [3, 4] Onset is typically thought to occur during childhood or young adulthood, but 30–40% of the adults with asthma had their initial presentation after the age of 40 [5]. Up to 52% of asthmatic patients had their “first asthma attack” after 40 years of age [6]. Asthma that starts in middle or older age (late-onset asthma, LOA) is frequently undiagnosed; it is believed to be “normal” in old age due to lack of fitness and reduced activity. This may lead to delayed treatment [7]. About 20% of subjects with LOA previously had received a diagnosis of chronic obstructive pulmonary disease (COPD) [8].

Due to aging-related changes in respiratory pathology and immunity, LOA is frequently not diagnosed or is misdiagnosed [9]. Unlike early-onset asthma (EOA), atopic changes are unlikely in LOA, but the types of antigen sensitization exposures in LOA and EOA are unclear [10]. There is also a lack of characterization of differences in inflammation between LOA and EOA. While eosinophilic inflammation is a typical feature of asthma [11], in LOA, eosinophils may have decreased effector functions, but evidence on their role in airway hyper-responsiveness (AHR) is conflicting [12].
Most LOA patients enrolled in studies had been pre-
scribed inhaled corticosteroids (ICS), oral corticosteroids
(OCs), or leukotriene receptor blockers, which mask natural
disease features and hamper research into the underlying
mechanisms [13–15]. It is difficult to recruit patients with
asthma at their initial presentation prior to pharmacologic
interventions. Although LOA is associated with distinct
phenotypic characteristics and immunologic levels, the
factors associated with the development of LOA are unclear.
In this study, we sought to better understand the factors
associated with EOA and LOA, and their clinical and
pathophysiologic features in Chinese patients.

2. Materials and Methods

2.1. Study Setting and Design. A single-center, population-
based, cross-sectional study was carried out in Zhongshan
Hospital, Fudan University, Shanghai, China. This 2430-bed
tertiary hospital is used by 10 million people in Shanghai and
150 million people in the surrounding Yangtze River Delta.
More than 260,000 outpatients are referred to the Depart-
ment of Pulmonary Medicine annually. All subjects signed
informed consent forms and the study was approved by the
Institutional Review Board, Human Subjects Research
Protection Program Office (B2018-010R) at Zhongshan
Hospital, Fudan University.

2.2. Study Subjects. Subjects were screened from the
Screening and Monitoring for Obstructive Lung Disease
project from February 2018 to October 2019. A total of
12,760 patients with cough, sputum, or chest tightness were
referred to the Department of Pulmonary Medicine. We
excluded 5085 patients with lung infection, lung shadow at
chest xRay, or lung mass, and 3260 patients with previous
diagnosis of asthma and/or COPD or already on medication
with drugs for chronic obstructive airway disease. The
remaining 1822 patients underwent pulmonary function
and/or bronchodilator reversibility testing. If the spirometry
results did not support the suspicion of asthma, the patients
were subjected to peak expiratory flow (PEF) monitoring
(Circassia Medical Device Co., Ltd., Morrisville, NC, USA).
Finally, 308 patients were diagnosed with asthma or COPD
at the initial presentation by the pulmonologist or the at-
tending physician according to the Global Initiative for
Asthma (GINA) and the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria [1,16]. The study
flow chart is given in Figure 1.

Before performing spirometry examination and col-
lecting blood samples, patients under medication for other
indications were asked to stop the related medication for at
least 7–10 days (e.g., cough syrup, Chinese traditional
medicine, and bronchodilator). Briefly, adults with respir-
atory symptoms, as indicated by an increase in forced
expiratory volume in 1 second (FEV1) of >12% and >200 mL
from baseline, 10–15 minutes after 200–400 mcg salbutamol
(albuterol) or a change in PEF of at least 20% from baseline
after 4 weeks of anti-inflammatory treatment, were con-
sidered as positive for diagnosis of asthma [1,17]. A case was
defined as EOA or LOA if the subject was diagnosed at age
<39 or ≥40, respectively, as previously recommended
[15, 18].

COPD was defined as any incidence of dyspnoea, chronic
cough, or sputum production, with a history of recurrent lower respiratory tract infections and/or a history of
exposure to risk factors for the disease and post-bron-
chodilator FEV1/forced vital capacity (FVC) < 0.7 with
chronic respiratory symptoms [16, 19]. All patients with
lung infection, lung shadow or mass, previous asthma and/
or COPD diagnosis, and age <18 years were excluded.
Healthy controls who reported no history of smoking or
respiratory disease were recruited for the study.

2.3. Data Collection. Clinical information of all patients was
carefully collected, including age, gender, weight, height,
body mass index (BMI), smoking history (smoking ≥1
 cigarette per day for 1 year), family history, related disease
history, and asthma severity. Subjects with asthma were
classified as mild, well controlled with step 1 and 2
treatments (e.g., monotherapy ICS or other single agent),
moderate, well controlled with step 3 treatment (e.g., ICS
plus one additional controller medication), or severe with
step 4 or step 5 treatment (e.g., ICS plus ≥2 additional
asthma control medications) based on the GINA criteria
and National Institutes of Health guidelines [1, 20].
According to the Global Initiative for Chronic Obstructive
Lung Disease–(GOLD) Classification of airflow limitation
severity in COPD (based on post-bronchodilator FEV1),
patients with FEV1/FVC < 0.70 were divided into mild
(GOLD1), FEV₁ ≥ 80% pred; moderate (GOLD2), 50% ≤ FEV₁ < 80% pred; severe (GOLD3), 30% ≤ FEV₁ < 50% pred; and very severe (GOLD4), FEV₁ < 30% pred, based on post-bronchodilator FEV₁ values in the GOLD guidelines [16, 21].

All subjects underwent allergy testing for specific immunoglobulin E (sIgE) in serum (Uranus AE65, China), and blood cell counts were performed [22]. Pulmonary function tests (Jaeger, Master Screen PFT, Germany) included FEV₁% pred, FEV₁ (L), FVC% pred, FVC (L), FEV₁/FVC (%), and bronchodilator reversibility testing in accordance with the American Thoracic Society guideline [23]. Fractional exhaled nitric oxide (FeNO) was also measured (NIOX VERO, Circassia Medical Device Co., Ltd.).

2.4. Statistical Analysis. Clinical characteristics are reported as means ± standard deviation or percentages. Continuous variables were analyzed by one-way analyses of variance, and categorical variables were assessed with Kruskal-Wallis tests [19]. Correlations between the percentage of blood basophils with gender, BMI, smoking history, family history, rhinitis, white cell counts, the percentage and absolute values of blood eosinophils, the absolute value of blood basophils, the percentage and absolute values of blood neutrophils, FEV₁% pred, FEV₁ (L), FVC% pred, FVC (L), FEV₁/FVC (%), and FeNO, allergens, and sIgE were evaluated by Spearman’s rank tests [11]. All tests were two-sided, and p values < 0.05 were considered statistically significant. Statistical analyses were conducted with SPSS for Windows, version 24.0 (IBM Corp., Armonk, NY, USA).

3. Results
3.1. Patient Characteristics. After enrollment and screening, a total of 308 patients were diagnosed with asthma or COPD at their initial presentation (Figure 1). Based on the age at initial presentation, a total of 308 patients were diagnosed with EOA (mean age 28.73 ± 5.89 years, range 18–39) and 111 patients with LOA (mean age 60.25 ± 9.85 years, range 41–80). Further 106 patients were diagnosed with COPD (mean age 61.58 ± 10.95 years, range 38–84). In the EOA and LOA groups, the gender distribution was roughly 60% male and 40% female, compared to approximately 70% and 30%, respectively, in the COPD group. The patients’ clinical characteristics are listed in Table 1.

There were no differences in BMI among the groups. However, the subgroup of female patients with LOA had a higher BMI compared to female patients in the EOA group (p < 0.05). Subjects with LOA were less likely to report a diagnosis of allergic rhinitis compared to those with EOA (52.7% vs. 80%), and COPD patients had the highest rate of smoking history (62.3%) among the three groups. With regard to asthma severity, LOA patients were more likely to be categorized as moderate (52.3% vs. 46.7%) or severe (25.2% vs. 14.4%) compared to those with EOA. In the COPD group, most of the patients belonged to GOLD1 class (39.6%) compared to the other subgroups (29.2%, 24.5, 6.6% for GOLD 2, 3, and 4, respectively).

Whereas the subgroup of female patients with LOA had a higher BMI compared to female patients in the EOA group (p < 0.05). Subjects with LOA were less likely to report a diagnosis of allergic rhinitis compared to those with EOA (52.7% vs. 80%), and COPD patients had the highest rate of smoking history (62.3%) among the three groups. With regard to asthma severity, LOA patients were more likely to be categorized as moderate (52.3% vs. 46.7%) or severe (25.2% vs. 14.4%) compared to those with EOA. In the COPD group, most of the patients belonged to GOLD1 class (39.6%) compared to the other subgroups (29.2%, 24.5, 6.6% for GOLD 2, 3, and 4, respectively).

### Table 1: Patient clinical characteristics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>EOA</th>
<th>LOA</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n)</td>
<td>90</td>
<td>111</td>
<td>106</td>
</tr>
<tr>
<td>Age (years)</td>
<td>28.73 ± 5.89</td>
<td>60.25 ± 9.85</td>
<td>61.58 ± 10.95</td>
</tr>
<tr>
<td>Age (range)</td>
<td>18–39</td>
<td>41–80</td>
<td>38–84</td>
</tr>
<tr>
<td>Male (%)</td>
<td>54 (60)</td>
<td>66 (59.5)</td>
<td>76 (71.7)</td>
</tr>
<tr>
<td>Female (%)</td>
<td>36 (40)</td>
<td>45 (40.5)</td>
<td>30 (28.3)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>67.45 ± 13.7</td>
<td>65.32 ± 11.49</td>
<td>66.65 ± 10.56</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.7 ± 0.09</td>
<td>1.65 ± 0.08</td>
<td>1.67 ± 0.07</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.26 ± 3.37</td>
<td>24.1 ± 3.78</td>
<td>23.96 ± 3.46</td>
</tr>
<tr>
<td>BMI female</td>
<td>5 (5.6)</td>
<td>38 (25)</td>
<td>66 (62.3)</td>
</tr>
<tr>
<td>Smoking history (%)</td>
<td>63 (70)</td>
<td>36 (32.1)</td>
<td>17 (16)</td>
</tr>
<tr>
<td>Family history (%)</td>
<td>72 (80)</td>
<td>59 (52.7)</td>
<td>13 (12.3)</td>
</tr>
<tr>
<td>Rhinitis (%)</td>
<td>35 (38.9)</td>
<td>25 (22.5)</td>
<td>—</td>
</tr>
<tr>
<td>GOLD</td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
</tr>
<tr>
<td>GOLD1</td>
<td>—</td>
<td>—</td>
<td>42 (39.6)</td>
</tr>
<tr>
<td>GOLD2</td>
<td>—</td>
<td>—</td>
<td>31 (29.2)</td>
</tr>
<tr>
<td>GOLD3</td>
<td>—</td>
<td>—</td>
<td>26 (24.5)</td>
</tr>
<tr>
<td>GOLD4</td>
<td>—</td>
<td>—</td>
<td>7 (6.6)</td>
</tr>
</tbody>
</table>

Data are shown as mean±SD or n (%). BMI, body mass index; COPD, chronic obstructive pulmonary disease; EOA, early-onset asthma; GOLD, Global Initiative for Chronic Obstructive Lung Disease; LOA, late-onset asthma. *p < 0.05 LOA vs. EOA.

3.2. Lung Function Tests and Allergic Features. The lung function test and allergic features were depicted in Figure 2(a)–2(c). FEV₁/FVC (%), FEV₁% pred, and FVC% pred were all significantly lower in LOA compared to EOA (p < 0.01). The values of post-bronchodilator FEV₁ in bronchodilator reversibility testing were higher in the LOA and EOA groups compared to subjects with COPD (p < 0.01). Moreover, although FeNO was lower in LOA compared to EOA, both groups showed significantly higher FeNO compared to the COPD group (p < 0.01). Respiratory physiology information is shown in Figure 2(a) and Supplementary Table S1.

There was a marked difference in allergic sensitization between the LOA and EOA groups (Figure 2(b), Supplementary Table S1). Sensitization to mites was most common in EOA patients (n = 74, 82.2%, p < 0.01), followed by LOA (n = 48, 42.9%, p < 0.05) and COPD (n = 5, 4.7%). However, more subjects with LOA showed sensitization to mold compared to EOA (14.3% vs. 1.1%, p < 0.05). Furthermore, the LOA group exhibited more sensitivity to Aspergillus fumigatus than the EOA group (13.4% vs. 1.1%, p = 0.053).

3.3. Inflammatory Blood Cell Counts. As shown in Table 2, the levels of blood eosinophils (absolute values and percentages) were increased in both LOA and EOA compared to COPD and healthy controls (p < 0.01). Interestingly, blood basophils (absolute values and percentages) were also increased in both LOA and EOA. Blood basophil levels were the highest in EOA patients (p < 0.01), followed by LOA (p < 0.05), compared to COPD and healthy controls. There
Figure 2: Continued.
were no differences in blood neutrophils (absolute value and percentage) among the LOA, EOA, COPD, and healthy control groups.

3.4. Correlation Analysis. The clinical significance of blood basophil counts in the study is demonstrated in Table 3. For EOA patients, the percentage of blood basophils was positively correlated with the percentage of blood eosinophils \( r = 0.549, \ p = 0.002 \) and the absolute value of blood eosinophils \( r = 0.496, \ p < 0.001 \). Although blood basophils were increased in LOA \( p < 0.05 \) compared to COPD and healthy controls, this was not correlated with any clinical parameter in the LOA group (Table 2).

4. Discussion

This was a single-center, population-based, cross-sectional study to describe the clinical characteristics in patients with LOA, with an emphasis on assessing the natural disease course without pharmacologic interventions. The main findings of the study include: (1) Atopy was less common in LOA compared to EOA, but the antigen sensitization profiles were different. Sensitization to mites was most frequent in EOA, followed by LOA and COPD. SubjectswithLOAweresignificantlymorelikelythanthosewithEOAtoshowsensitizationtomold. (2) Spirometry values were lower in patients with LOA compared to EOA at their initial presentation. (3) Blood eosinophils were a typical feature in both the LOA and EOA groups. Number of blood basophils were also increased and correlated with eosinophils in EOA but not with LOA. There were no differences in blood neutrophils among subjects with LOA or EOA and healthy controls.

Table 2: Blood cells count data of participants.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>EOA (n = 90)</th>
<th>LOA (n = 111)</th>
<th>COPD (n = 106)</th>
<th>LOA-controls (n = 30)</th>
<th>EOA-controls (n = 30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>White cell counts (×10^9/L)</td>
<td>7.11 ± 1.84</td>
<td>6.97 ± 1.99</td>
<td>6.58 ± 1.77</td>
<td>6.34 ± 1.11</td>
<td>6.68 ± 0.9</td>
</tr>
<tr>
<td>Blood eosinophils (%)</td>
<td>4.54 ± 2.80</td>
<td>4.63 ± 4.39</td>
<td>1.64 ± 1.09</td>
<td>2.2 ± 1.7</td>
<td>1.88 ± 1.03</td>
</tr>
<tr>
<td>Blood basophils (×10^9/L)</td>
<td>0.33 ± 0.24</td>
<td>0.33 ± 0.34</td>
<td>0.10 ± 0.07</td>
<td>0.14 ± 0.11</td>
<td>0.12 ± 0.06</td>
</tr>
<tr>
<td>Blood neutrophils (%)</td>
<td>54.51 ± 9.04</td>
<td>55.01 ± 16.55</td>
<td>59.73 ± 17.18</td>
<td>56.17 ± 7.28</td>
<td>56.38 ± 6.39</td>
</tr>
<tr>
<td>Blood neutrophils (×10^9/L)</td>
<td>4.83 ± 3.94</td>
<td>6.13 ± 10.09</td>
<td>6.44 ± 11.99</td>
<td>3.54 ± 0.91</td>
<td>3.87 ± 0.88</td>
</tr>
</tbody>
</table>

Data are shown as mean ± SD. COPD, chronic obstructive pulmonary disease; EOA, early-onset asthma; LOA, late-onset asthma. *p < 0.01 EOA and LOA vs. COPD and LOA-controls and EOA-controls; †p < 0.05 EOA and COPD and LOA-controls and EOA-controls; ‡p < 0.01 EOA vs. COPD and COPD-controls and EOA-controls.

Figure 2: Lung function test and allergic features. (a) Spirometry results. \( p < 0.01 \) EOA vs. LOA; \( p < 0.01 \) EOA and LOA vs. COPD. (b) The percentage of allergens. \( p < 0.05 \) LOA vs. EOA and COPD; \( p < 0.01 \) EOA vs. COPD. (c) Reversibility for FVC.
obesity is a risk factor for LOA [28]. Interestingly, BMI values in females with COPD and LOA were similar (Table 1). Further studies are needed to confirm the results and to identify the mechanism.

Our findings showed a major difference in the atopic sensitization between LOA and EOA. The Epidemiology and Natural History of Asthma (TENOR) study found that subjects with LOA had less allergic rhinitis and fewer patients with sIgE to at least one allergen [29], which is in accordance with the current study. However, antigen sensitization differed between the LOA and EOA groups. Sensitization to mites was most common in the EOA group, followed by LOA and COPD. Sensitization to mold was significantly more likely in LOA compared to EOA. Furthermore, *Aspergillus fumigatus* sensitivity was increased in LOA compared to EOA. This suggests that sensitization to mold in patients with LOA may be related to their living and work environment [30], and epigenetic changes may also contribute to different phenotypes of asthma [31, 32].

Compared to younger cohorts, subjects with LOA have more severe asthma and higher rates of AHR. In our study, LOA patients were more likely to be categorized as moderate (52.3% vs. 46.7%) or severe (25.2% vs. 14.4%) compared to those with EOA. Spirometry values were also significantly lower in patients with LOA compared to EOA at their initial presentation, which is similar to a previous report [33]. However, post-bronchodilator FEV1 values in bronchodilator reversibility testing were higher in both LOA and EOA groups compared to COPD. A reasonable explanation for this is age-related physiological changes that may act synergistically with asthma to worsen airflow obstruction, including less elastic recoil, increased airway remodeling in smaller airways, increased thickness of the central airway wall, and increased inflammation [12].

Eosinophilic inflammation is a typical feature of asthma. Many studies reported that levels of blood eosinophils were similar to those of airway eosinophils in asthma [34, 35]. This is similar to our finding that blood eosinophils were increased in both LOA and EOA compared to COPD and healthy controls. Other studies reported that airway basophils were increased and correlated with airway and blood eosinophil levels, whereas airway and blood basophils were not correlated [11, 36]. Indeed, basophils are rare granulocytes in the blood and have been considered as effector cells in allergic disease [37, 38]. When we divided asthma patients into LOA and EOA cohorts, blood basophils were increased in both LOA and EOA compared to COPD and controls. Interestingly, blood basophils correlated with the percentage of blood eosinophils and the absolute value of blood eosinophils in EOAs but not in LOA. The proportion or composition of inflammatory cells may contribute to pathophysiological differences between EOA and LOA. Finally, there were no differences in blood neutrophils among EOA, LOA, and healthy controls in the study, which is in accordance with a previous report that neutrophils were not associated with LOA [39]. Further studies are required to substantiate our findings. Although previous studies have tried to address the factors associated with the development of EOA and LOA, there are no prediction models for determining the risk factors for developing EOA and LOA. Our current study provided insights into the probable factors associated with EOA and LOA. The causal relationships need to be elucidated in future studies.

There are limitations to our study. Airway inflammation could not be assessed as sputum induction was not performed due to the high concentration of saline, which could exacerbate asthma symptoms in patients without medication-controlled disease [11]. LOA with overlapping COPD was also difficult to distinguish in this cross-sectional study [1]. Furthermore, the cross-sectional nature of the study may also introduce reporting bias and since some data were self-reported by the subjects, there could also be recall bias. Similarly, since our medical center is exclusive for adult patients, we have not included children and adolescents with EOA which could have contributed to inclusion bias of the study. Nevertheless, the large representative sample included in the study negates the limitations to a certain extent.
5. Conclusions

LOA is a distinct clinical entity from EOA. In LOA, atopy was less frequent compared to EOA and antigen sensitization differences may be related to their living and work environments. Spirometry values were lower for LOA patients at their initial presentation than EOA patients. In EOA, blood basophils and eosinophils were significantly correlated.

COPD, chronic obstructive pulmonary disease; EOA, early-onset asthma; LOA, late-onset asthma.

Data Availability

All data or resources used in the current study are available from the corresponding author upon reasonable request.

Disclosure

This work has been previously presented as a poster at the American Thoracic Society International Conference, 2020.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

SJ and SYL were responsible for study concept and design; LJ and YL were involved in data acquisition; YL and SJ analyzed and interpreted the data; SJ drafted the manuscript; and SYL revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors thank Prof. Zhu Lei for pulmonary function test instruction and Zhifeng Zhang for technical assistance. The authors acknowledge Prof L. Shi and C. Bai for their assistance in data collection. This work was sponsored by Shanghai Municipal Key Clinical Specialty (shslczzd022001) and Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02013); National Natural Science Foundation of China (81770075); Science and Technology Commission of Shanghai Municipality (20XD1401200 and 20Z11901000); and National Key R&D Plan (2020YFC2003700); SJ was sponsored by the Shanghai Pujiang Program (16PJD012).

Supplementary Materials

Table S1: lung function test and allergy status in the study. (Supplementary Materials)

References


